For drugs delivery, biocompatible, efficient, and controllable systems are the requirements that spurred the evolution of different polymers material. Alginate, a naturally occurring polysaccharide made from brown seaweed, is particularly popular for its biocompatibility, biodegradability and hydrogel properties. This flexibility has led to the role of alginate in drug delivery systems for controlled release and targeted therapy. The low viscosity version of Alginate AMCA (aminomethyl coumarin conjugated alginate) has the efficacy of drug delivery has been enhanced, meanwhile being more manageable in viscosity. This particular AMCA-enhanced version of alginate has fluorescent features that allow real-time tracking and monitoring of drug delivery systems – an important aspect of personalized medicine and treatment optimization. This low viscosity version of Alginate AMCA is especially useful for producing solutions that are easier to formulate and take which make it an ideal candidate for many different types of drug delivery applications from oral to injectable. The functionalisation of alginate with AMCA (aminomethylcoumarin) gives us a fluorescent signal with which we can map how drugs circulate and diffuse throughout the body. This monitoring potential is crucial for optimal drug timing and dosage in the clinic because researchers and clinicians can monitor the activity of the drug composition in real time. Alginate AMCA's low viscosity, in turn, alleviates injection and formulation stability concerns for use in applications requiring exact control of drug release. This low viscosity also means that the solution is able to be used for a wider variety of applications such as injectable gels and microparticles where high viscosity can create issues with dispense and dispersal. If made low viscosity, then againate allows the formulation of drug delivery devices that are both convenient and that deliver therapeutics over an extended period of time. This makes it the perfect candidate for local and systemic delivery of drugs that increases treatment efficiency and accessibility. Among the most promising properties of low viscosity Alginate AMCA for drug delivery is the gel networks when it encounters divalent cations, especially calcium ions. Such gelation is a method that can also package all manner of therapeutic substances from small molecules to proteins and nucleic acids. The low viscosity nature of this modified alginate means that the gel doesn't require excessive alginate concentrations that could otherwise make it difficult to formulate (such as not injectable or not homogeneous). The inclusion of AMCA further gives you the added advantage of monitoring in real time the release kinetics of the encapsulated drug. Since AMCA fluoresces on stimulation, drug release can be directly measured with the variation in fluorescence. It allows us to measure how the drug acts in the body, where the release occurs, and how efficient is the delivery system of the drug, all without the use of invasive techniques. This is particularly useful in preclinical and clinical applications where the pharmacokinetics of a drug dosage form is an essential part of treatment planning and optimization.
Figure 1. Gelatin/alginate solutions at different concentrations. (Jin W, et al.; 2022)
The way that Alginate AMCA, Low Viscosity delivers drugs is based largely on the alginate polymer, combined with the fluorescent AMCA label. Because alginate is a polyelectrolyte, it will gelify in contact with divalent cations (usually calcium ions). The end result is a hydrogel matrix that is stable and it contains the active ingredient. Because of this low viscosity adjustment, this gelation occurs at a relatively low concentration of alginate and so is easier to prepare and deliver. AMCA reactivity transforms the gel into a fluorescence signal, so we can passively track the release and movement of the drug in the body. When exposed to calcium ions, the chains of alginate unwind to form a network of gels, which surround the active molecules and regulate their ejection. Low viscosity Alginate AMCA is suitable for drug delivery applications as microparticle, nanoparticle or hydrogel, whose benefits can vary with application. Alginate AMCA-based products can, for example, be developed for drug delivery via oral suppositories to form controlled-release devices that shield the drug from breakdown in the GI tract and release it slowly and continuously. This formulation is viscous, making it easy to be administered, and the medication's encapsulation in the gel matrix improves the drug's stability and bioavailability. The AMCA's fluorescence also provides the possibility of monitoring the drug molecule throughout the GI tract, which can provide insights into release profiles and dosing timings. The virtualisation of the drug's release in real-time also gives a window on how the drug acts on the body and helps to build more effective drug delivery systems. Viscosity-low Alginate AMCA is also used for injectable drug delivery systems. When given as a gel or particulate, the solution can be injected into the body and will gel at the site of the injection for local, long-lasting drug delivery. This local delivery can be especially useful in treatment that needs to be performed at a specific location (for instance, for cancer treatments or for healing wounds). As gelation can be regulated by the presence of calcium or other divalent cations, the rate of release of the encapsulated drug can be precisely controlled according to the patients' treatment requirements. Also, the low viscosity means the drug formulation is not confined to high-pressure syringes, which is easier for patients and physicians to administer. That is something to consider when designing drug delivery systems for chronic conditions, where the ease of use and comfort of the patient are paramount.
There are many advantages of drug delivery with Alginate AMCA, Low Viscosity compared to the traditional methods. It is biocompatible and biodegradable, one of the biggest advantages. Alginate is a naturally occurring polysaccharide, and the body tolerates it well so no risk of adverse immune reaction occurs with alginate in pharmaceuticals. And alginate gels are biodegradable — that is, they disintegrate slowly inside the body and disperse the medicine carefully, leaving no toxic degradation products. This is a very important feature for long-term safety, especially in the case of chronic conditions or longer-term therapy. The fluorescence of the AMCA change is another plus. Real-time delivery and release of drugs opens up new potential for drug therapy optimization. Clinical staff can watch the development of the drug delivery system, adjusting accordingly, leading to better treatment results, using fluorescent imaging. This ability can be useful especially for preclinical studies to tweak formulations and release profiles prior to clinical trials. Real-time drug delivery could be leveraged in the clinic to customise medications for patients, modifying drug release rates and doses according to patient responses and disease course. In the future, Alginate AMCA combined with low viscosity may transform many aspects of drug delivery, including targeted and personalised medicine. Leveraging this formulation's specificity, scientists can design more precise and effective drug delivery systems for all therapeutic fields, from oncology and immunotherapy to gene therapy and regenerative medicine. In addition, the use of nanotechnology and smart drug delivery could be made possible even more precisely by controlling the release of drugs. The potential for more complex, patient-directed therapies may be very good for stimuli-responsive alginate formulations, for instance, which release drugs in response to environmental (such as pH or temperature). Furthermore, Alginate AMCA-based solutions that are low viscosity could be further optimized for minimally invasive delivery with microneedles or transdermal patches to provide a new avenue of delivery with reduced patient discomfort and compliance.
Alternate Names:
Low-Viscosity Alginate-AMCA Conjugate
Alginate-AMCA Derivative
Alginate-AMCA Complex
AMCA-Labeled Alginate
Fluorescent Alginate
Low-Viscosity Fluorescent Alginate
References:
1. Jin W, et al.; Effect of Hydrogel Contact Angle on Wall Thickness of Artificial Blood Vessel. Int J Mol Sci. 2022, 23(19):11114.
Datasheet